SO
SPRY icon

STRS Ohio’s ARS Pharmaceuticals SPRY Stock Holding History

STRS Ohio’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-24,000
Closed -$253K – 2012
2024
Q4 		$253K Hold
24,000
– – ﹤0.01% 1424
2024
Q3 		$348K Buy
+24,000
New +$285K ﹤0.01% 1402
2021
Q2 		– Sell
-3,100
Closed -$135K – 2417
2021
Q1 		$135K Buy
+3,100
New +$147K ﹤0.01% 1880

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

STRS Ohio's SPRY Position: Q1 2025 in Review

STRS Ohio sold out of ARS Pharmaceuticals (SPRY) in Q1 2025, closing a stake of 24,000 shares — an estimated $253K sold.

STRS Ohio first reported a position in SPRY in Q1 2021 and held it in 3 quarters. The position peaked at $348K in Q3 2024. 184 funds tracked by Wall St. Rank hold SPRY as of Q1 2025.

  • STRS Ohio reported no remaining ARS Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • STRS Ohio sold 24,000 ARS Pharmaceuticals shares in Q1 2025, an estimated $253K.
  • STRS Ohio first reported a position in ARS Pharmaceuticals in Q1 2021 and held it in 3 quarters.
  • STRS Ohio's ARS Pharmaceuticals position peaked at $348K in Q3 2024.
  • 184 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2025.

Based on STRS Ohio's 13F filing for Q1 2025, filed 28 May 2025.